The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of chronic viral hepatitis B

The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of... Summary An individual's iron status may affect the response rate achieved with the use of interferon (IFN) as therapy for chronic viral hepatitis. A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n= 14) or in combination with cycles of deferoxamine at a dose of 80 mg kg‐1 per cycle (n= 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml‐1. All deferoxamine‐treated patients were on a low iron‐containing diet. An IFN response was defined as a normalization of the serum alanine aminotransferase (ALT) level and seroconversion from hepatitis B e antigen (HBeAg) positivity to hepatitis B e antibody (HBeAb) positivity. The deferoxamine‐treated group experienced a reduction in their serum ferritin level to 226 ± 73 ng ml‐1 as a result of the deferoxamine treatment. Six of the 13 (46%) deferoxamine‐treated patients and two of the 14 (14%) control patients normalized their ALT levels. Seven of the 13 (54%) deferoxamine but only 14% of the IFN‐treated group seroconverted to HBeAb positivity. A greater rate of histological improvement and loss of hepatitis B virus (HBV) DNA was seen in the deferoxamine‐treated group. Two of the deferoxamine‐treated patients were treated only once, two were treated twice, seven were treated three times and two were treated four times to achieve a ferritin level below 250 ng ml‐1. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Viral Hepatitis Wiley

The use of deferoxamine infusions to enhance the response rate to interferon‐α treatment of chronic viral hepatitis B

Loading next page...
 
/lp/wiley/the-use-of-deferoxamine-infusions-to-enhance-the-response-rate-to-jRw0GewV7R
Publisher
Wiley
Copyright
Copyright © 1996 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1352-0504
eISSN
1365-2893
DOI
10.1111/j.1365-2893.1996.tb00003.x
Publisher site
See Article on Publisher Site

Abstract

Summary An individual's iron status may affect the response rate achieved with the use of interferon (IFN) as therapy for chronic viral hepatitis. A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n= 14) or in combination with cycles of deferoxamine at a dose of 80 mg kg‐1 per cycle (n= 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml‐1. All deferoxamine‐treated patients were on a low iron‐containing diet. An IFN response was defined as a normalization of the serum alanine aminotransferase (ALT) level and seroconversion from hepatitis B e antigen (HBeAg) positivity to hepatitis B e antibody (HBeAb) positivity. The deferoxamine‐treated group experienced a reduction in their serum ferritin level to 226 ± 73 ng ml‐1 as a result of the deferoxamine treatment. Six of the 13 (46%) deferoxamine‐treated patients and two of the 14 (14%) control patients normalized their ALT levels. Seven of the 13 (54%) deferoxamine but only 14% of the IFN‐treated group seroconverted to HBeAb positivity. A greater rate of histological improvement and loss of hepatitis B virus (HBV) DNA was seen in the deferoxamine‐treated group. Two of the deferoxamine‐treated patients were treated only once, two were treated twice, seven were treated three times and two were treated four times to achieve a ferritin level below 250 ng ml‐1.

Journal

Journal of Viral HepatitisWiley

Published: May 1, 1996

References

  • Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein
    Sibille, Sibille; Kondo, Kondo; Aisen, Aisen
  • Dual effect of deferoxamine on free radical formation and reoxygenation injury in isolated hepatocytes
    Caraceni, Caraceni; Van Thiel, Van Thiel; Borle, Borle
  • Human natural killer cells lysis of virus‐infected cells. Relationship to expression of the transferrin receptor
    Borysiewicz, Borysiewicz; Graham, Graham; Sissons, Sissons
  • Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine
    Olivieri, Olivieri; Berriman, Berriman; Tyler, Tyler
  • Recombinant leukocyte interferon treatment of chronic hepatitis B
    Dusheiko, Dusheiko; DiBisceglie, DiBisceglie; Bowyer, Bowyer
  • Loss of HBsAg with interferon therapy in chronic hepatitis virus infection
    Alexander, Alexander
  • A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy
    Saracco, Saracco; Mazzella, Mazzella; Rosina, Rosina

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month